16248-Lymphomas-Non-Hodgkins-421

Lymphomas

An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

  • Details

ClinicalTrials.gov ID: NCT01897571
Diagnosis Type: Non-Hodgkins
USOR Number: 16248

  • Address

433 SW 10th Street
Ocala, FL 34471
P: (352) 732-4032

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.